Incidence, risk factors, and outcomes of second neoplasms in patients with acute promyelocytic leukemia: the PETHEMA-PALG experience.
Acute promyelocytic leukemia
Chemotherapy based and chemotherapy free regimens
Outcomes
Risk factors
Second neoplasms
Journal
Annals of hematology
ISSN: 1432-0584
Titre abrégé: Ann Hematol
Pays: Germany
ID NLM: 9107334
Informations de publication
Date de publication:
19 Dec 2023
19 Dec 2023
Historique:
received:
29
07
2023
accepted:
05
12
2023
medline:
19
12
2023
pubmed:
19
12
2023
entrez:
19
12
2023
Statut:
aheadofprint
Résumé
The most important challenges in acute promyelocytic leukemia (APL) is preventing early death and reducing long-term events, such as second neoplasms (s-NPLs). We performed a retrospective analysis of 2670 unselected APL patients, treated with PETHEMA "chemotherapy based" and "chemotherapy free" protocols. Only de novo APL patients who achieved complete remission (CR) and completed the three consolidation cycles were enrolled into the analysis. Out of 2670 APL patients, there were 118 (4.4%) who developed s-NPLs with the median latency period (between first CR and diagnosis of s-NPL) of 48.0 months (range 2.8-231.1): 43.3 (range: 2.8-113.9) for s-MDS/AML and 61.7 (range: 7.1-231.1) for solid tumour. The 5-year CI of all s-NPLs was of 4.43% and 10 years of 7.92%. Among s-NPLs, there were 58 cases of s-MDS/AML, 3 cases of other hematological neoplasms, 57 solid tumours and 1 non-identified neoplasm. The most frequent solid tumour was colorectal, lung and breast cancer. Overall, the 2-year OS from diagnosis of s-NPLs was 40.6%, with a median OS of 11.1 months. Multivariate analysis identified age of 35 years (hazard ratio = 0.2584; p < 0.0001) as an independent prognostic factor for s-NPLs. There were no significant differences in CI of s-NPLs at 5 years between chemotherapy-based vs chemotherapy-free regimens (hazard ratio = 1.09; p = 0.932). Larger series with longer follow-up are required to confirm the potential impact of ATO+ATRA regimens to reduce the incidence of s-NPLs after front-line therapy for APL.
Identifiants
pubmed: 38110588
doi: 10.1007/s00277-023-05582-y
pii: 10.1007/s00277-023-05582-y
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s).
Références
Lo-Coco F, Ammatuna E, Montesinos P et al (2008) Acute promyelocytic leukemia: recent advances in diagnosis and management. Semin Oncol 35:401–409
doi: 10.1053/j.seminoncol.2008.04.010
pubmed: 18692690
Sanz MA, Grimwade D, Tallman MS et al (2009) Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 113:1875–1891
doi: 10.1182/blood-2008-04-150250
pubmed: 18812465
Fenaux P, Chastang C, Chevret S et al (1999) A randomized comparison of all trans retinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood 14:1192–1200
doi: 10.1182/blood.V94.4.1192
Sanz MA, Martin G, Gonzalez M et al (2004) Risk adapted treatment of acute promyelocytic leukemia with all trans retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood 103:1237–1243
doi: 10.1182/blood-2003-07-2462
pubmed: 14576047
Sanz MA, Montesinos P, Rayon C et al (2010) Risk adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. Blood 115:5137–5146
doi: 10.1182/blood-2010-01-266007
pubmed: 20393132
Mandelli F, Diverio D, Avvisati G et al (1997) Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. Blood 90:1014–1021
pubmed: 9242531
Lengfelder E, Haferlach C, Saussele S et al (2010) High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCG. Leukemia 2009;23:2248-58. Lo CoCo Blood 116:3171–3179
Tallman MS, Andersen JW, Schiffer CA et al (1997) All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 337:1021–1028
doi: 10.1056/NEJM199710093371501
pubmed: 9321529
Huang ME, Ye YC, Chen SR et al (1988) Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72:572
doi: 10.1182/blood.V72.2.567.567
Estey E, Garcia-Manero G, Ferrajoli A et al (2006) Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood 107:3469–3473
doi: 10.1182/blood-2005-10-4006
pubmed: 16373661
Lo-Coco F, Avvisati G, Vignetti M et al (2013) Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 369:111–121
doi: 10.1056/NEJMoa1300874
pubmed: 23841729
Platzbecker U, Avvisati G, Cicconi L et al (2017) Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non-high-risk acute promyelocytic leukemia: final results of the randomized Italian-German APL0406 trial. J Clin Oncol 35:605–612
doi: 10.1200/JCO.2016.67.1982
pubmed: 27400939
Pagano L, Gimema F, Pulsoni A et al (2004) Second malignancy after treatment of adult acute myeloid leukemia: cohort study on adult patients enrolled in the GIMEMA trials. Leukemia 18:651–653
doi: 10.1038/sj.leu.2403276
pubmed: 14749702
Montesinos P, González JD, González J et al (2010) Therapy-related myeloid neoplasms in patients with acute promyelocytic leukemia treated with all-trans-retinoic acid and anthracycline-based chemotherapy. J Clin Oncol 28:3872–3879
doi: 10.1200/JCO.2010.29.2268
pubmed: 20625122
Zompi S, Viguié F (2002) Therapy-related acute myeloid leukemia and myelodysplasia after successful treatment of acute promyelocytic leukemia. Leuk Lymphoma 43:275–280
doi: 10.1080/10428190290006044
pubmed: 11999558
Batzios C, Hayes LA, He SZ, Quach H, McQuilten ZK, Wall M, Campbell LJ (2009) Secondary clonal cytogenetic abnormalities following successful treatment of acute promyelocytic leukemia. Am J Hematol 84:715–719 Erratum in: Am J Hematol. 2010;85:550
doi: 10.1002/ajh.21528
pubmed: 19806661
Lobe I, Rigal-Huguet F, Vekhoff A, Desablens B, Bordessoule D, Mounier C, Ferrant A, Sanz M, Fey M, Chomienne C, Chevret S, Degos L, Fenaux P, European APL group experience (2003) Myelodysplastic syndrome after acute promyelocytic leukemia: the European APL group experience. Leukemia 17:1600–1604
doi: 10.1038/sj.leu.2403034
pubmed: 12886249
Latagliata R, Petti MC, Fenu S et al (2002) Therapy-related myelodysplastic syndrome-acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: an emerging problem. Blood 99:822–824
doi: 10.1182/blood.V99.3.822
pubmed: 11806982
Lenzi L, Lee-Jones L, Mostofa MA, de Andrade DP, Ribeiro RC, Figueiredo BC (2020) Second primary malignancy after acute promyelocytic leukemia: a population-based study. Cancers (Basel) 12:3610
doi: 10.3390/cancers12123610
pubmed: 33287098
Kayser S, Rahmé R, Martínez-Cuadrón D et al (2020) Outcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide-an International Collaborative Study. Leukemia 34:2333–2341
doi: 10.1038/s41375-020-0758-4
pubmed: 32076120
pmcid: 8318880
Norsworthy KJ, Avagyan A, Bird ST et al (2020) Second cancers in adults with acute promyelocytic leukemia treated with or without arsenic trioxide: a SEER-medicare analysis. Leukemia 34:3082–3084
doi: 10.1038/s41375-020-0905-y
pubmed: 32518418
Eghtedar A, Rodriguez I, Kantarjian H, O'Brien S, Daver N, Garcia-Manero G, Ferrajoli A, Kadia T, Pierce S, Cortes J, Ravandi F (2015) Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid plus arsenic trioxide. Leuk Lymphoma 56:1342–1345
doi: 10.3109/10428194.2014.953143
pubmed: 25120050
Giri S, Pathak R, Aryal MR et al (2017) Second primary malignancy in acute promyelocytic leukemia: a surveillance, epidemiology and end results database study. Futur Oncol 13:1455–1457
doi: 10.2217/fon-2017-0077
Pedersen-Bjergaard J, Andersen MK, Christiansen DH (2000) Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation. Blood 95:3273–3279
doi: 10.1182/blood.V95.11.3273
pubmed: 10828005
Pedersen-Bjergaard J, Philip P, Larsen SO et al (1993) Therapy-related myelodysplasia and acute myeloid leukemia. Cytogenetic characteristics of 115 consecutive cases and risk in seven cohorts of patients treated intensively for malignant diseases in the Copenhagen series. Leukemia 7:1975–1986
Chen QY, DesMarais T, Costa M (2019) Metals and mechanisms of carcinogenesis. Annu Rev Pharmacol Toxicol 59:537–554
doi: 10.1146/annurev-pharmtox-010818-021031
pubmed: 30625284
pmcid: 6348465
Liu G, Song Y, Li C et al (2021) Arsenic compounds: the wide application and mechanisms applied in acute promyelocytic leukemia and carcinogenic toxicology. Eur J Med Chem 221:113519
doi: 10.1016/j.ejmech.2021.113519
pubmed: 33984805
Treatment of acute promyelocytic leukemia PETHEMA LPA 2012, PETHEMA/PALG protocol
Treatment of acute promyelocytic leukemia PETHEMA LPA 2017, PETHEMA/PALG protocol
Cheson BD, Bennett JM, Kopecky KJ et al (2003) Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 21:4642–4649
doi: 10.1200/JCO.2003.04.036
pubmed: 14673054
Sanz MA, Fenaux P, Tallman MS et al (2019) Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. Blood 133:1630–1643
doi: 10.1182/blood-2019-01-894980
pubmed: 30803991
pmcid: 6509567
Arber DA, Orazi A, Hasserjian R et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127:2391–2405
doi: 10.1182/blood-2016-03-643544
pubmed: 27069254
Labrador J, Luño E, Vellenga E et al (2019) Clinical significance of complex karyotype at diagnosis in pediatric and adult patients with de novo acute promyelocytic leukemia treated with ATRA and chemotherapy. Leuk Lymphoma 60:1146–1155
doi: 10.1080/10428194.2018.1522438
pubmed: 30526152
Kaplan EL, Meier P (1958) Nonparametric estimations from incomplete observations. J Am Stat Assoc 53:457–481
doi: 10.1080/01621459.1958.10501452
Mantel N (1966) Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163–170
pubmed: 5910392
Gray RJ (1988) A class of K-sample test for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141–1154
doi: 10.1214/aos/1176350951
Aalen O (1978) Nonparametric estimation of partial transition probabilities in multiple decrement models. Ann Stat 6:534–545
Cox DR (1972) Regression models and life tables (with discussion). J R Stat Soc B 34:187–220
Morton LM, Onel K, Curtis RE et al (2014) The rising incidence of second cancers: patterns of occurrence and identification of risk factors for children and adults. Am Soc Clin Oncol Educ Book:e57–e67
Andersen MK, Pedersen-Bjergaard J (2002) Therapy-related MDS and AML in acute promyelocytic leukemia. Blood 100:1928–1929 author reply 1929
doi: 10.1182/blood-2002-03-0962
pubmed: 12211197
Cervera J, Montesinos P, Hernández-Rivas JM et al (2010) Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Haematologica 95:424–431
doi: 10.3324/haematol.2009.013243
pubmed: 19903674
Sessarego M, Fugazza G, Balleari E et al (1997) High frequency of trisomy 8 in acute promyelocytic leukemia: a fluorescence in situ hybridization study. Cancer Genet Cytogenet 97:161–164
doi: 10.1016/S0165-4608(96)00323-8
pubmed: 9283601
Sobas M, Rodriguez-Veiga R, Vellenga E et al (2020) PETHEMA, HOVON, PALG, GATLA cooperative groups. Characteristics and outcome of adult patients with acute promyelocytic leukemia and increased body mass index treated with the PETHEMA Protocols. Eur J Haematol. 104(3):162–169
doi: 10.1111/ejh.13346
pubmed: 31724208